Xinlitai announced that the company recently received the “Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to carry out clinical trials of the innovative siRNA drug Sal0195 injection independently developed by the company to treat increased lipoprotein. SAL0195 has a long-term effect of target knockout in a preclinical monkey model that lasts 140 days with a single dose.

Zhitongcaijing · 2d ago
Xinlitai announced that the company recently received the “Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to carry out clinical trials of the innovative siRNA drug Sal0195 injection independently developed by the company to treat increased lipoprotein. SAL0195 has a long-term effect of target knockout in a preclinical monkey model that lasts 140 days with a single dose.